vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Voyager Technologies, Inc. (VOYG). Click either name above to swap in a different company.
Voyager Technologies, Inc. is the larger business by last-quarter revenue ($35.2M vs $18.7M, roughly 1.9× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -130.4%, a 129.5% gap on every dollar of revenue. On growth, Voyager Technologies, Inc. posted the faster year-over-year revenue change (2.1% vs -25.7%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-66.8M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs VOYG — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $35.2M |
| Net Profit | $-154.0K | $-45.9M |
| Gross Margin | — | -4.4% |
| Operating Margin | -6.9% | — |
| Net Margin | -0.8% | -130.4% |
| Revenue YoY | -25.7% | 2.1% |
| Net Profit YoY | 97.6% | -64.5% |
| EPS (diluted) | — | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $35.2M | ||
| Q4 25 | — | $46.7M | ||
| Q3 25 | — | $39.6M | ||
| Q2 25 | $18.7M | $45.7M | ||
| Q1 25 | $50.9M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $25.1M | — |
| Q1 26 | — | $-45.9M | ||
| Q4 25 | — | $-33.0M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | $-154.0K | $-31.4M | ||
| Q1 25 | $23.5M | — | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | — | ||
| Q2 24 | $-6.5M | — |
| Q1 26 | — | -4.4% | ||
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 15.4% | ||
| Q2 25 | — | 18.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -60.7% | ||
| Q2 25 | -6.9% | -52.8% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — |
| Q1 26 | — | -130.4% | ||
| Q4 25 | — | -70.7% | ||
| Q3 25 | — | -41.1% | ||
| Q2 25 | -0.8% | -68.7% | ||
| Q1 25 | 46.2% | — | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | — | ||
| Q2 24 | -26.0% | — |
| Q1 26 | — | $-0.75 | ||
| Q4 25 | — | $-0.52 | ||
| Q3 25 | — | $-0.28 | ||
| Q2 25 | — | $-1.23 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $429.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $404.5M |
| Total Assets | $175.1M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $429.4M | ||
| Q4 25 | — | $491.3M | ||
| Q3 25 | — | $413.3M | ||
| Q2 25 | $49.0M | $468.9M | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — |
| Q1 26 | — | $404.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $590.9M | ||
| Q2 25 | $119.9M | $554.7M | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | — | ||
| Q2 24 | $-31.2M | — |
| Q1 26 | — | $1.0B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $727.8M | ||
| Q2 25 | $175.1M | $685.3M | ||
| Q1 25 | $98.5M | — | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | — | ||
| Q2 24 | $159.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-39.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $-66.8M |
| FCF MarginFCF / Revenue | -84.6% | -189.5% |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-263.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-39.7M | ||
| Q4 25 | — | $-60.9M | ||
| Q3 25 | — | $-15.1M | ||
| Q2 25 | $-15.8M | $-30.9M | ||
| Q1 25 | $-21.0M | — | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.5M | — |
| Q1 26 | — | $-66.8M | ||
| Q4 25 | — | $-54.5M | ||
| Q3 25 | — | $-53.8M | ||
| Q2 25 | $-15.8M | $-88.8M | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — |
| Q1 26 | — | -189.5% | ||
| Q4 25 | — | -116.9% | ||
| Q3 25 | — | -135.8% | ||
| Q2 25 | -84.6% | -194.4% | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 97.8% | ||
| Q2 25 | 0.1% | 126.7% | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
VOYG
Segment breakdown not available.
